Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Biotechnology

Healthcare
$9.38 +0.00%

+$0.00 today

Market cap
$622.71M
Beta
-0.53
P/E (TTM)
-8.8
EPS (TTM)
-$2.59
52W Low $8.48High $24.25

Volume 1.30M

Average 0.54M

BCAX Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Bicara Therapeutics Inc. Common StockNASDAQ: BCAX

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI turns negative

Q1 FY2026 Accumulated OCI was -$243K, compared with $0 a year earlier.

Context

  • Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$243K— QoQ
Last fiscal yearDec 2025
$243K— YoY
Year agoMar 2025
$0— since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
243K USD
Year-over-year change
—

Accumulated OCI vs competitors

How BCAX compares with its peers on the latest reported figures

  • BCAX's Mar 2026 Accumulated OCI of -$243K is the lowest of the 6 companies compared; the peer median is $0.
  • Accumulated OCI amounts to 0.0% of total assets for BCAX, versus a peer median of 0.0%.
BCAX Competitors Peer median
Accumulated OCI for BCAX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CGEMCullinan Therapeutics, Inc.Mar 2026$127K -74.9%—0.0%
CBIOCrescent Biopharma, Inc.Mar 2026$0 ——0.0%
CNTXContext Therapeutics Inc.Mar 2026$0 ——0.0%
MGNXMacroGenics, Inc.Mar 2026-$27K -2600.0%—0.0%
CMPXCompass Therapeutics, Inc.Mar 2026-$159K -183.7%—0.1%
BCAXBicara Therapeutics Inc. Common StockMar 2026-$243K ——0.0%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding BCAX) $0-183.7%—0.0%

Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents4.16M230.44M489.71M96.69M
Short-term Investments000318.12M
Net Receivables0000
Inventory0000
Other Current Assets68K100K12.82M7.25M
Total Current Assets4.98M231.07M502.53M422.05M
Property, Plant & Equipment (Net)636K815K845K2.03M
Goodwill0000
Intangible Assets0000
Long-term Investments0000
Tax Assets0059.2M0
Other Non-current Assets1.08M2.09M6.62M6.91M
Total Non-current Assets1.72M2.91M66.66M8.94M
Total Assets6.7M233.98M569.2M430.99M
Account Payables5.14M3.19M4.51M5.52M
Short-term Debt00607K0
Tax Payables0000
Deferred Revenue0000
Other Current Liabilities009.79M22.32M
Total Current Liabilities23.9M15.09M17.99M28.95M
Long-term Debt0000
Deferred Tax Liabilities0059.2M0
Deferred Revenue (Non-current)0000
Other Non-current Liabilities85K17K00
Total Non-current Liabilities85K389K59.33M593K
Total Liabilities23.98M15.47M77.32M29.54M
Common Stock2K2K7K7K
Retained Earnings(101.04M)(153.02M)(221.02M)(358.97M)
Accumulated OCI000243K
Other Stockholders Equity0000
Minority Interest0000
Total Equity(17.28M)218.51M491.88M401.45M
Total Debt0657K738K1.71M
Net Debt(4.16M)(229.78M)(488.97M)(94.98M)

Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Intrinsic Alpha fair value

Locked

Current Price

$9.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.